Eloxx Pharmaceuticals (ELOX) Stock Statistics & Valuation Metrics

Eloxx Pharmaceuticals has a market cap or net worth of $70.44M. The enterprise value is $13.98.

Eloxx Pharmaceuticals has 4,036,459 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eloxx Pharmaceuticals’s return on equity (ROE) is 0.50 and return on invested capital (ROIC) is 59.03%.

The current PE Ratio of Eloxx Pharmaceuticals is ―. Eloxx Pharmaceuticals’s PEG ratio is 0.05.

In the last 12 months, Eloxx Pharmaceuticals had revenue of 0.00 and earned -6.00M in profits. Earnings per share was -5.34.

In the last 12 months, operating cash flow was -10.24M and capital expenditures 0.00, giving a free cash flow of -10.24M billion.

Eloxx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Eloxx Pharmaceuticals upcoming earnings date is Nov 11, 2026, TBA (Confirmed).

Eloxx Pharmaceuticals as a current ratio of 0.31, with Debt / Equity ratio of 0.00%

In the past 12 months, Eloxx Pharmaceuticals has paid 0.00 in taxes.

Eloxx Pharmaceuticals EV to EBITDA ratio is -1.73, with an EV/FCF ratio of 0.00.

Eloxx Pharmaceuticals has $61.96M in cash and marketable securities with $0.00 in debt, giving a net cash position of $61.96M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Eloxx Pharmaceuticals is $38.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy